vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and USA Compression Partners, LP (USAC). Click either name above to swap in a different company.

USA Compression Partners, LP is the larger business by last-quarter revenue ($252.5M vs $129.5M, roughly 1.9× Arcutis Biotherapeutics, Inc.). Arcutis Biotherapeutics, Inc. runs the higher net margin — 13.4% vs 11.0%, a 2.4% gap on every dollar of revenue. On growth, Arcutis Biotherapeutics, Inc. posted the faster year-over-year revenue change (81.5% vs 2.7%). Over the past eight quarters, Arcutis Biotherapeutics, Inc.'s revenue compounded faster (70.1% CAGR vs 4.9%).

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

USA Compression Partners, LP is a US-based provider of natural gas compression services and related infrastructure solutions. It serves clients across the upstream, midstream, and downstream segments of the oil and gas industry, offering custom compression systems, maintenance, and operational support to facilitate efficient natural gas production, processing, and transportation.

ARQT vs USAC — Head-to-Head

Bigger by revenue
USAC
USAC
1.9× larger
USAC
$252.5M
$129.5M
ARQT
Growing faster (revenue YoY)
ARQT
ARQT
+78.8% gap
ARQT
81.5%
2.7%
USAC
Higher net margin
ARQT
ARQT
2.4% more per $
ARQT
13.4%
11.0%
USAC
Faster 2-yr revenue CAGR
ARQT
ARQT
Annualised
ARQT
70.1%
4.9%
USAC

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
ARQT
ARQT
USAC
USAC
Revenue
$129.5M
$252.5M
Net Profit
$17.4M
$27.8M
Gross Margin
91.0%
Operating Margin
14.2%
30.3%
Net Margin
13.4%
11.0%
Revenue YoY
81.5%
2.7%
Net Profit YoY
9.1%
EPS (diluted)
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
USAC
USAC
Q2 26
$129.5M
Q1 26
$105.4M
Q4 25
$129.5M
$252.5M
Q3 25
$99.2M
$250.3M
Q2 25
$81.5M
$250.1M
Q1 25
$65.8M
$245.2M
Q4 24
$71.4M
$245.9M
Q3 24
$44.8M
$240.0M
Net Profit
ARQT
ARQT
USAC
USAC
Q2 26
$17.4M
Q1 26
$-11.3M
Q4 25
$17.4M
$27.8M
Q3 25
$7.4M
$34.5M
Q2 25
$-15.9M
$28.6M
Q1 25
$-25.1M
$20.5M
Q4 24
$-10.8M
$25.4M
Q3 24
$-41.5M
$19.3M
Gross Margin
ARQT
ARQT
USAC
USAC
Q2 26
91.0%
Q1 26
90.7%
Q4 25
91.0%
Q3 25
91.2%
Q2 25
90.8%
Q1 25
86.6%
Q4 24
90.3%
Q3 24
87.7%
Operating Margin
ARQT
ARQT
USAC
USAC
Q2 26
14.2%
Q1 26
-8.6%
Q4 25
14.2%
30.3%
Q3 25
8.6%
33.5%
Q2 25
-17.9%
30.6%
Q1 25
-37.3%
28.3%
Q4 24
-10.7%
30.3%
Q3 24
-87.3%
31.5%
Net Margin
ARQT
ARQT
USAC
USAC
Q2 26
13.4%
Q1 26
-10.7%
Q4 25
13.4%
11.0%
Q3 25
7.5%
13.8%
Q2 25
-19.5%
11.4%
Q1 25
-38.1%
8.4%
Q4 24
-15.1%
10.3%
Q3 24
-92.8%
8.1%
EPS (diluted)
ARQT
ARQT
USAC
USAC
Q2 26
$0.13
Q1 26
$-0.09
Q4 25
$0.14
Q3 25
$0.06
Q2 25
$-0.13
Q1 25
$-0.20
Q4 24
$-0.09
Q3 24
$-0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
USAC
USAC
Cash + ST InvestmentsLiquidity on hand
$42.9M
$8.6M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$189.5M
Total Assets
$433.0M
$2.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
USAC
USAC
Q2 26
$42.9M
Q1 26
$34.8M
Q4 25
$42.9M
$8.6M
Q3 25
$47.1M
Q2 25
$72.7M
$2.0K
Q1 25
$53.1M
$2.0K
Q4 24
$71.3M
$14.0K
Q3 24
$134.9M
$79.0K
Total Debt
ARQT
ARQT
USAC
USAC
Q2 26
Q1 26
Q4 25
$109.0M
$2.5B
Q3 25
$108.5M
$2.5B
Q2 25
$108.0M
$2.5B
Q1 25
$107.6M
$2.5B
Q4 24
$107.2M
$2.5B
Q3 24
$204.6M
$2.5B
Stockholders' Equity
ARQT
ARQT
USAC
USAC
Q2 26
$189.5M
Q1 26
$189.6M
Q4 25
$189.5M
Q3 25
$158.1M
Q2 25
$139.0M
Q1 25
$142.7M
Q4 24
$157.5M
Q3 24
$156.6M
Total Assets
ARQT
ARQT
USAC
USAC
Q2 26
$433.0M
Q1 26
$460.0M
Q4 25
$433.0M
$2.6B
Q3 25
$371.0M
$2.7B
Q2 25
$352.4M
$2.7B
Q1 25
$344.1M
$2.7B
Q4 24
$348.9M
$2.7B
Q3 24
$437.4M
$2.8B
Debt / Equity
ARQT
ARQT
USAC
USAC
Q2 26
Q1 26
Q4 25
0.58×
Q3 25
0.69×
Q2 25
0.78×
Q1 25
0.75×
Q4 24
0.68×
Q3 24
1.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
USAC
USAC
Operating Cash FlowLast quarter
$139.5M
Free Cash FlowOCF − Capex
$87.7M
FCF MarginFCF / Revenue
34.8%
Capex IntensityCapex / Revenue
20.5%
Cash ConversionOCF / Net Profit
5.02×
TTM Free Cash FlowTrailing 4 quarters
$277.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
USAC
USAC
Q2 26
Q1 26
Q4 25
$26.2M
$139.5M
Q3 25
$-1.8M
$75.9M
Q2 25
$324.0K
$124.2M
Q1 25
$-30.4M
$54.7M
Q4 24
$-748.0K
$130.2M
Q3 24
$-34.7M
$48.5M
Free Cash Flow
ARQT
ARQT
USAC
USAC
Q2 26
Q1 26
Q4 25
$87.7M
Q3 25
$51.9M
Q2 25
$246.0K
$101.1M
Q1 25
$-31.0M
$36.3M
Q4 24
$101.2M
Q3 24
$-34.8M
$19.8M
FCF Margin
ARQT
ARQT
USAC
USAC
Q2 26
Q1 26
Q4 25
34.8%
Q3 25
20.7%
Q2 25
0.3%
40.4%
Q1 25
-47.1%
14.8%
Q4 24
41.1%
Q3 24
-77.8%
8.2%
Capex Intensity
ARQT
ARQT
USAC
USAC
Q2 26
Q1 26
Q4 25
0.0%
20.5%
Q3 25
0.0%
9.6%
Q2 25
0.1%
9.3%
Q1 25
0.9%
7.5%
Q4 24
0.0%
11.8%
Q3 24
0.3%
12.0%
Cash Conversion
ARQT
ARQT
USAC
USAC
Q2 26
Q1 26
Q4 25
1.51×
5.02×
Q3 25
-0.24×
2.20×
Q2 25
4.35×
Q1 25
2.66×
Q4 24
5.12×
Q3 24
2.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARQT
ARQT

Segment breakdown not available.

USAC
USAC

Revenue From Contract Operations Excluding Revenue From Related Party$231.7M92%
Entities Affiliated With Energy Transfer LP$16.6M7%
Transferred At Point In Time$5.4M2%

Related Comparisons